Evotec-Roche Deal Indicates Adoption of Mass Spec, Hi-Res Instrumentation for Clinical Protein Quant | GenomeWeb

NEW YORK (GenomeWeb) – Evotec said this week that it has achieved a milestone in its protein biomarker work with Roche, as the drugmaker selected for phase I clinical trial use a response prediction marker developed through the two firms' collaboration.

Significantly, Roche plans to use mass spectrometry for measuring that marker and related maker signatures in the clinical setting, Dirk Ullman, Evotec's executive VP, lead discovery, told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.